Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BI 765080 in healthy male subjects
NCT04666922Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2021
- Primary completion
- Aug 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of BI 765080 in chronic kidney disease (CKD) (7 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Percentage of Subjects With Drug-related Adverse Events up to 87 days. Started Jan 2021; status: completed.
02
Drugs
BI 765080
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT04666922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04666922.